Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.23)
# 4,379
Out of 5,182 analysts
9
Total ratings
25%
Success rate
-28.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Outperform | $45 → $32 | $14.80 | +116.22% | 2 | Apr 2, 2026 | |
| INCY Incyte | Maintains: In-Line | $73 → $110 | $95.55 | +15.12% | 2 | Mar 5, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $38.66 | +24.16% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $11.56 | +159.52% | 2 | Mar 22, 2023 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $0.92 | +2,406.54% | 1 | May 25, 2021 |
Viridian Therapeutics
Apr 2, 2026
Maintains: Outperform
Price Target: $45 → $32
Current: $14.80
Upside: +116.22%
Incyte
Mar 5, 2026
Maintains: In-Line
Price Target: $73 → $110
Current: $95.55
Upside: +15.12%
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $38.66
Upside: +24.16%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $11.56
Upside: +159.52%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $0.92
Upside: +2,406.54%